Sonoma Pharmaceuticals (SNOA) Change in Receivables (2010 - 2026)
Sonoma Pharmaceuticals' (SNOA) quarterly Change in Receivables came in at $168000.0 in Q1 2026, up 178.14% year-on-year from $60401.3 in Q1 2025, and up 149.41% quarter-over-quarter from -$340000.0 in Q4 2025.
Sonoma Pharmaceuticals (SNOA) Change in Receivables (2010 - 2026) Analysis & Trends
Sonoma Pharmaceuticals' Change in Receivables history runs 17 years deep, the most recent figure standing at $168000.0 for Q1 2026.
- On a quarterly basis, Change in Receivables rose 178.14% year-over-year to $168000.0 in Q1 2026; TTM through Mar 2026 was $122000.0, a 128.11% increase from a year earlier, with the FY2026 full-year figure at $122000.0, up 128.11% from the prior year.
- Change in Receivables climbed to $168000.0 in Q1 2026 per SNOA's latest filing, from -$340000.0 in the prior quarter.
- Across five years, Change in Receivables topped out at $596000.0 in Q4 2023 and bottomed at -$2.0 million in Q1 2022.
- The 5-year median for Change in Receivables is $9000.0 (2024), against an average of -$123941.2.
- Across the five-year window, Change in Receivables soared 346.07% in 2024 and sank 2488.89% in 2025, its largest moves.
- Year by year, Change in Receivables stood at -$289000.0 in 2022, then soared by 306.23% to $596000.0 in 2023, then plunged by 208.39% to -$646000.0 in 2024, then surged by 47.37% to -$340000.0 in 2025, then surged by 149.41% to $168000.0 in 2026.
- Per Business Quant, the three latest SNOA Change in Receivables figures stand at $168000.0 (Q1 2026), -$340000.0 (Q4 2025), and $78000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | -78.00 Mn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | 106.00 Mn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | -621.82 Mn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | -38.20 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | 126.30 Mn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 81.40 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | - |
| 10 | Sonoma Pharmaceuticals | 1.95 Mn | -445,560.06 | 2.18 Mn | 168,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 168,000.00 |
| Mar 31, 2026 | 168,000.00 |
| Dec 31, 2025 | -340,000.00 |
| Dec 31, 2025 | -340,000.00 |
| Sep 30, 2025 | 78,000.00 |
| Sep 30, 2025 | 78,000.00 |
| Jun 30, 2025 | 216,000.00 |
| Jun 30, 2025 | 216,000.00 |
| Mar 31, 2025 | -215,000.00 |
| Mar 31, 2025 | -215,000.00 |
| Dec 31, 2024 | -646,000.00 |
| Dec 31, 2024 | -646,000.00 |
| Sep 30, 2024 | -43,000.00 |
| Sep 30, 2024 | -43,000.00 |
| Jun 30, 2024 | 470,000.00 |
| Jun 30, 2024 | 470,000.00 |
| Mar 31, 2024 | 9,000.00 |
| Mar 31, 2024 | 9,000.00 |
| Dec 31, 2023 | 596,000.00 |
| Dec 31, 2023 | 596,000.00 |